Vanda Pharmaceuticals (VNDA) Competitors $5.00 -0.10 (-1.96%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VNDA vs. GOSS, AKUS, ANAB, ALBO, OPK, IRWD, EBS, SGMO, RIGL, and XOMAShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Gossamer Bio (GOSS), Akouos (AKUS), AnaptysBio (ANAB), Albireo Pharma (ALBO), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Sangamo Therapeutics (SGMO), Rigel Pharmaceuticals (RIGL), and XOMA (XOMA). These companies are all part of the "medical" sector. Vanda Pharmaceuticals vs. Gossamer Bio Akouos AnaptysBio Albireo Pharma OPKO Health Ironwood Pharmaceuticals Emergent BioSolutions Sangamo Therapeutics Rigel Pharmaceuticals XOMA Gossamer Bio (NASDAQ:GOSS) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Which has more risk and volatility, GOSS or VNDA? Gossamer Bio has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Does the media favor GOSS or VNDA? In the previous week, Gossamer Bio had 16 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 19 mentions for Gossamer Bio and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.77 beat Gossamer Bio's score of 0.58 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in GOSS or VNDA? Vanda Pharmaceuticals received 386 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 66.96% of users gave Vanda Pharmaceuticals an outperform vote while only 66.23% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15166.23% Underperform Votes7733.77% Vanda PharmaceuticalsOutperform Votes53766.96% Underperform Votes26533.04% Do insiders and institutionals hold more shares of GOSS or VNDA? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is GOSS or VNDA more profitable? Gossamer Bio has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -8.59%. Vanda Pharmaceuticals' return on equity of -3.02% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Vanda Pharmaceuticals -8.59%-3.02%-2.52% Which has stronger valuation & earnings, GOSS or VNDA? Vanda Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$105.32M1.59-$179.82M-$0.32-2.31Vanda Pharmaceuticals$190.86M1.53$2.51M-$0.28-17.86 Do analysts prefer GOSS or VNDA? Gossamer Bio presently has a consensus price target of $9.20, suggesting a potential upside of 1,143.08%. Vanda Pharmaceuticals has a consensus price target of $15.50, suggesting a potential upside of 210.00%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Vanda Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVanda Pharmaceuticals beats Gossamer Bio on 10 of the 17 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$291.54M$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-17.8610.1698.9217.12Price / Sales1.53266.571,205.7371.29Price / CashN/A53.4940.6936.36Price / Book0.549.306.325.87Net Income$2.51M$154.14M$119.47M$225.66M7 Day Performance-3.66%-9.49%-5.11%-1.34%1 Month Performance2.04%-7.23%-3.21%1.00%1 Year Performance47.93%30.70%32.41%25.27% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.3127 of 5 stars$5.00-2.0%$15.50+210.0%+47.9%$291.54M$192.64M-17.86203Analyst ForecastGOSSGossamer Bio4.3817 of 5 stars$0.85-0.9%N/A-10.3%$192.39MN/A-2.66180Short Interest ↓Analyst RevisionNews CoverageAKUSAkouosN/A$13.29flatN/A+0.0%$490.88MN/A-5.07103ANABAnaptysBio2.5896 of 5 stars$21.75-2.9%N/A+33.2%$661.85M$17.16M-3.58100Analyst ForecastALBOAlbireo PharmaN/A$44.15-0.2%N/A+0.0%$913.91M$40.58M-6.57130OPKOPKO Health4.6578 of 5 stars$1.61+2.2%N/A+14.7%$1.12B$863.50M-8.453,930Insider BuyingIRWDIronwood Pharmaceuticals4.2073 of 5 stars$4.40-7.9%N/A-55.4%$702.86M$442.73M-146.67220Analyst DowngradeShort Interest ↓EBSEmergent BioSolutions4.4029 of 5 stars$10.98-8.3%N/A+264.2%$594.94M$1.07B-2.681,600Analyst UpgradeSGMOSangamo Therapeutics2.2761 of 5 stars$2.68-0.7%N/A+484.5%$558.03M$12.28M-1.94480Earnings ReportAnalyst ForecastAnalyst RevisionRIGLRigel Pharmaceuticals3.9843 of 5 stars$28.84+15.6%N/A+197.5%$507.30M$116.88M206.01147Analyst ForecastNews CoverageXOMAXOMA4.4351 of 5 stars$31.48+1.0%N/A+104.1%$368.44M$9.81M-9.0510Insider SellingShort Interest ↓ Related Companies and Tools Related Companies Gossamer Bio Competitors Akouos Competitors AnaptysBio Competitors Albireo Pharma Competitors OPKO Health Competitors Ironwood Pharmaceuticals Competitors Emergent BioSolutions Competitors Sangamo Therapeutics Competitors Rigel Pharmaceuticals Competitors XOMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VNDA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts